<< مقالات لاتين >>
<< بر اساس عنوان >>
1
Hepatic Involvement in Dengue Fever in Children
2
Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C
3
Hepatic iron concentration, fibrosis and response to venesection associated with the A77D and V162del “loss of function” mutations in ferroportin disease
4
Hepatic iron metabolism gene expression profiles in HFE associated Hereditary Hemochromatosis
5
Hepatic iron overload and fibrosis in patients with beta thalassemia major after hematopoietic stem cell transplantation: A pilot study.
6
Hepatic iron overload and hepatocellular carcinoma
7
Hepatic iron overload in alcoholic liver disease: why does it occur and what is its role in pathogenesis?
8
Hepatic iron status and response to therapy in chronic viral hepatitis B and C: A preliminary report
9
Hepatic Ischemia and Reperfusion Injury and Trauma: Current Concepts
10
Hepatic ischemia secondary to hepatic artery ligation: MRI findings
11
Hepatic Ischemia/Reperfusion Injury Is Diminished by Atorvastatin in Wistar Rats
12
Hepatic ischemia-reperfusion injury
13
Hepatic ischemia-reperfusion injury
14
Hepatic levels of metal and metallothioneins in two commercial fish species of the Northern Iberian shelf
15
Hepatic lipase mediates an increase in selective uptake of high-density lipoprotein-associated cholesteryl esters by human Hep 3B hepatoma cells in culture Original Research Article
16
Hepatic lipase mediates lipoprotein uptake into cells via LDL receptor-related protein
17
Hepatic lipase mutations,elevated high-density lipoprotein cholesterol, and increased risk of ischemic heart disease: The Copenhagen City Heart Study
18
Hepatic lipase promoter activity is reduced by the C-480T and G-216A substitutions present in the common LIPC gene variant, and is increased by Upstream Stimulatory Factor
19
Hepatic lipase promoter C-514T polymorphism influences serial changes in HDL cholesterol levels since childhood: the Bogalusa Heart Study
20
Hepatic lipid accumulation, altered very low density lipoprotein formation and apolipoprotein E deposition in apolipoprotein E3-Leiden transgenic mice
21
Hepatic lipid composition analysis using 3.0-T MR spectroscopy in a steatotic rat model
22
Hepatic lipidosis in a common Mynah (Acridotheres tristis) associated with pododermatitis and consumption of broiler pelleted feed
23
Hepatic lipogenic enzyme expression in pigs is affected by selection for decreased backfat thickness at constant intramuscular fat content
24
Hepatic Lobectomy-Case Report of Two Patients, Performed at Chittagong Medical College Hospital
25
Hepatic localisation of rat cysteine dioxygenase
26
Hepatic mesenchymal hamartoma with translocation involving chromosome band 19q13.4: a recurrent abnormality
27
Hepatic metabolism of sulfur amino acids in db/db mice
28
Hepatic metabolism, phase I and II biotransformation enzymes in Atlantic salmon (Salmo Salar, L) during a 12 week feeding period with graded levels of the synthetic antioxidant, ethoxyquin
29
Hepatic metallothionein as a biomarker for metal contamination: age effects and seasonal variation in European flounders (Pleuronectes flesus) from the Severn Estuary and Bristol Channel
30
Hepatic metallothionein concentrations in the golden grey mullet (Liza aurata) – Relationship with environmental metal concentrations in a metal-contaminated coastal system in Portugal
31
Hepatic metastasis complicated by abscess formation
32
Hepatic Microcirculatory Changes Induced by Hepatic Artery Embolization in Rats Original Investigation
33
Hepatic microvascular features in experimental cirrhosis: a structural and morphometrical study in CCl4-treated rats
34
Hepatic mitochondrial transport of glutathione: Studies in isolated rat liver mitochondria and H4IIE rat hepatoma cells
35
Hepatic mono-oxygenase induction in benthic flatfish sampled near coastal pulp mills in British Columbia
36
Hepatic mucosa-associated lymphoid tissue (MALT) lymphoma associated with hepatitis C
37
Hepatic multi-nodular focal fatty metamorphosis in acquired porphyria cutanea tarda: Sonographic, CT, and mri features
38
Hepatic mycotic aneurysms
39
Hepatic myelopathy Case report with review of the literature
40
Hepatic myelopathy with spastic paraparesis
41
Hepatic necroinflammation and severe liver fibrosis in patients with chronic hepatitis B with undetectable HBV DNA and persistently normal alanine aminotransferase
42
Hepatic Necrosis: A Main Presentation of Systemic Lupus Erythematosus in a Previously Healthy Woman
43
Hepatic nodules in liver transplantation candidates: MR imaging and underlying hepatic disease
44
Hepatic Osteodystrophy: a relationship between osteoporotic bone and chronic liver disease
45
Hepatic OV-6 expression in human liver disease and rat experiments: evidence for hepatic progenitor cells in man
46
Hepatic oval cell lines generate hepatocellular carcinoma following transfection with HBx gene and treatment with aflatoxin B1 in vivo
47
Hepatic overlap syndromes
48
Hepatic oxidative alterations in patients with extra-hepatic cholestasis. Effect of surgical drainage
49
Hepatic Oxidative Damages and Glucose Tolerance in Diabetic Rats Exposed to Repeated Oral Doses of Diazinon
50
Hepatic oxidative DNA damage correlates with iron overload in chronic hepatitis C patients
51
Hepatic parenchymal enhancement at Gd-EOB-DTPA-enhanced MR imaging: correlation with morphological grading of severity in cirrhosis and chronic hepatitis
52
Hepatic parenchymal enhancement at Gd-EOB-DTPA-enhanced MR imaging: correlation with morphological grading of severity in cirrhosis chronic hepatitis
53
Hepatic phospholipids in alcoholic liver disease assessed by proton-decoupled 31P magnetic resonance spectroscopy
54
Hepatic portal venous gas
55
Hepatic portal venous gas: clinical significance of computed tomography findings
56
Hepatic production of VLDL1 but not VLDL2 is related to insulin resistance in normoglycaemic middle-aged subjects
57
Hepatic protection by perioperative metabolic support?
58
Hepatic protein synthesis rate of liver specimens as a predictor of viability in rat cold ischemia liver transplantation model
59
Hepatic Proteins and Inflammatory Markers in Rheumatoid Arthritis Patients
60
Hepatic pseudocapillarisation and atherosclerosis in ageing
61
Hepatic radiofrequency ablation using perfusion electrodes in a pig model: Effect of the Pringle manoeuvre
62
Hepatic reduction of insulin-like growth factor (IGF)-I and IGF binding protein-3 that results from fasting is not attenuated in genetically obese rats
63
Hepatic regeneration in insulin-like growth factor binding protein-1 transgenic mice
64
Hepatic release of interleukin-10 during cardiopulmonary bypass in steroid-pretreated patients, , , ,
65
Hepatic repopulation with stably transduced conditionally immortalized hepatocytes in the Gunn rat
66
Hepatic resection for hepatocellular carcinoma
67
Hepatic resection for hepatocellular carcinoma in Taiwan
68
Hepatic resection for large hepatocellular carcinoma
69
Hepatic resection for malignant melanoma
70
Hepatic resection for metastatic neuroendocrine carcinomas
71
Hepatic resection for recurrent metastatic ovarian cancer
72
Hepatic resection in breast cancer metastases: should it be considered standard treatment?
73
Hepatic resection in metastatic breast cancer: results and prognostic factors
74
Hepatic resection using stapling devices
75
Hepatic resection with vascular isolation and routine supraceliac aortic clamping
76
Hepatic retractor in an ex vivo model
77
Hepatic Rupture After Heimlich Maneuver
78
Hepatic Sarcodosis presenting as portal hypertension in a young boy
79
Hepatic sarcoidosis: MR appearances in patients with chronic liver disease
80
Hepatic Shock Differential Diagnosis and Risk Factors: A Review Article
81
Hepatic Sinusoidal Endothelial Cells Promote Hepatocyte Proliferation Early after Partial Hepatectomy in Rats
82
Hepatic sinusoidal-obstruction syndrome: toxicity of pyrrolizidine alkaloids
83
Hepatic Steatosis
84
Hepatic Steatosis Alleviated by a Novel Metformin and Quercetin Combination Activating Autophagy Through the cAMP/AMPK/SIRT1 Pathway
85
Hepatic Steatosis among Obese Children and Adolescents
86
Hepatic Steatosis and Fibrosis in Type 2 Diabetes: A Risk-Based Approach to Targeted Screening
87
Hepatic steatosis and insulin resistance: Does etiology make a difference?
88
Hepatic Steatosis and Related Factors in Obese Children Attending National Nutritional Institute
89
Hepatic steatosis and very low density lipoprotein secretion: the involvement of apolipoprotein E
90
Hepatic steatosis in chronic hepatitis B and C: Predictors, distribution and effect on fibrosis
91
Hepatic steatosis in HIV/HCV co-infected patients: Correlates, efficacy and outcomes of anti-HCV therapy: A paired liver biopsy study
92
Hepatic Steatosis in Iranian Patients with Chronic Hepatitis C
93
Hepatic steatosis is associated with a greater prevalence of coronary artery calcification in asymptomatic men
94
Hepatic steatosis: An experimental model for quantification
95
Hepatic stellate (ITO) cells: expanding roles for a liver-specific pericyte
96
Hepatic stellate cell activation in genetic haemochromatosis : Lobular distribution, effect of increasing hepatic iron and response to phlebotomy
97
Hepatic stellate cell activation occurs in nonalcoholic steatohepatitis
98
Hepatic stellate cell activation occurs in the absence of hepatitis in alcoholic liver disease and correlates with the severity of steatosis
99
Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers
100
Hepatic stellate cells (Ito-cells) but not collagen IV may partly be responsible for lower portal pressure after reversing secondary biliary cirrhosis in the rat
101
Hepatic stellate cells and the regulation of liver inflammation
102
Hepatic stellate cells are an important cellular site for β-carotene conversion to retinoid
103
Hepatic stellate cells become susceptible to fas-ligand induced apoptosis during transformation to myofibroblasts
104
Hepatic stellate cells do not derive from the neural crest
105
Hepatic stellate cells in human schistosomiasis mansoni: A comparative immunohistochemical study with liver cirrhosis
106
HEPATIC STELLATE CELLS IN THE CONTEXT OF LIVER FIBROSIS
107
Hepatic stem cells
108
Hepatic Stem-like Phenotype and Interplay of Wnt/β-Catenin and Myc Signaling in Aggressive Childhood Liver Cancer
109
Hepatic stress in hereditary tyrosinemia type 1 (HT1) activates the AKT survival pathway in the fah−/− knockout mice model
110
Hepatic tissue damage induced in Meriones ungliculatus due to infection with Babesia divergens-infected erythrocytes
111
Hepatic Tissue Engineering Using Scaffolds: State of the Art
112
Hepatic Toxocariasis in a Child: ACase Report from Shiraz, Southern Iran
113
Hepatic triacylglycerols and serum non-esterified fatty acids (NEFA) variations in indigenous water buffalo (Bubalus bubalis) in the province of Khuzestan, Iran
114
Hepatic tumor necrosis factors production and distant organ dysfunction in a murine model of obstructive jaundice
115
Hepatic tumours in childhood: An experience at the Children Hospital and Institute of Child Health, Lahore
116
Hepatic undifferentiated embryonal sarcoma: malignant evolution of mesenchymal hamartoma? Study of one case with immunohistochemical and flow cytometric emphasis
117
Hepatic vagotomy inhibits proliferation of hepatic stellate cells in rats with acute hepatitis
118
Hepatic vascular calcification: An early second trimester sonographic feature of idiopathic infantile arterial calcinosis
119
Hepatic vascular malformations in hereditary hemorrhagic telangiectasia: Doppler sonographic screening in a large family
120
Hepatic vein to the azygous vein anastomosis for pulmonary arteriovenous fistulae
121
Hepatic vein velocities in children with right ventricular hypertension
122
Hepatic vein waveform in liver cirrhosis: Correlation with Child’s class and size of varices
123
Hepatic veno-occlusive disease with immunodeficiency (VODI): First reported case in the U.S. and identification of a unique mutation in Sp110
124
Hepatic Venous Malformation After Modified Fontan Procedure With Partial Hepatic Vein Exclusion
125
Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy
126
Hepatic viral infections in Yemen between 2000-2005
127
Hepatic von Meyenburg complex simulating biliary cystadenocarcinoma
128
Hepatic, Renal and Cardiovascular Biomarker Variability in Type 2 Diabetes Mellitus Patients with Poor Glycemic Control
129
Hepaticocholecystoduodenostomy compared with Roux-en-y choledochojejunostomy for decompression of the biliary tract
130
Hepatiti C and Ocular urface Dieae Original Reearch Article
131
Hepatitis A 2004 Vaccination in Children: Methods and Findings of a Survey in Two States Original Research Article
132
Hepatitis A and B immunization in persons being evaluated for sexually transmitted diseases
133
Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus
134
Hepatitis A and E: not to be forgotten
135
Hepatitis A and vigorous physical activity
136
Hepatitis A booster vaccination: is there a need?
137
Hepatitis A Chronic Immunity in Iran: A Geographic Information System-Based Study
138
Hepatitis A Chronic Immunity: A Population-Based Seroprevalence Study in Fars Province, Southern Iran
139
Hepatitis A IgG seropositivity and coronary atherosclerosis assessed by angiography
140
HEPATITIS A IN LATIN AMERICA: A CHANGING EPIDEMIOLOGIC PATTERN
141
Hepatitis A in the Eastern Mediterranean Region: A Review on the Prevalence
142
Hepatitis A Infection Presented with Pancytopenia, a Case Series in Children
143
Hepatitis A Is a Health Hazard for Iranian Pilgrims Who Go to Holly Karbala: A Preliminary Report
144
Hepatitis A linked to clotting factors in USA
145
Hepatitis A Prevention Strategies, Haiti Case: Should Rescuers Be Immunized
146
Hepatitis A Seropositivity among First-Year Students of the Medical University in Isfahan, Iran
147
Hepatitis A seropositivity among newly admitted medical students of Isfahan, Kermanshah, and Hamedan: A seroprevalence study
148
Hepatitis a seroprevalence among young adults: Effects of ACIP immunization recommendations
149
Hepatitis A Seroprevalence and Associated Risk Factors: A Community-based Cross-sectional Study in Shahrekord, Iran
150
Hepatitis A Vaccination among Thai Medical Students: A Questionnaire Study
151
Hepatitis A vaccine failure
152
Hepatitis A vaccine for Israeli children
153
Hepatitis A vaccine for secondary hepatitis A infection
154
Hepatitis A vaccine for secondary hepatitis A infection
155
Hepatitis A vaccine for secondary hepatitis A infection
156
Hepatitis A vaccine for secondary hepatitis A infection
157
Hepatitis A vaccine for secondary hepatitis A infection
158
Hepatitis A vaccine in the last-minute traveler
159
Hepatitis A virus – a general overview
160
Hepatitis A Virus and Coronary Artery Diseases
161
Hepatitis A Virus and Hepatitis E Virus Seroprevalence Among Blood Donors in Tehran, Iran
162
Hepatitis A virus in environmental water samples from the Amazon Basin
163
Hepatitis A Virus Infection
164
Hepatitis A virus infection suppresses hepatitis C virus replication and may lead to clearance of HCV
165
Hepatitis A Virus Infection, Vaccination and Iranian Healthcare Workers
166
Hepatitis A virus infection: Is it an important hazard to public health?
167
Hepatitis A Virus Seropositivity in Nurses and Paramedical Personnel at a University Hospital in North Iran
168
Hepatitis A virus vaccination in Iranian soldiers needs more attention
169
Hepatitis A Virus: Is Vaccination Necessary in Middle East?
170
Hepatitis A Virus: Seroepidemiological Study in Fars Province
171
Hepatitis A with Pleural Effusion, Ascites and Acalculous Cholecystitis
172
Hepatitis after intravenous buprenorphine misuse in heroin addicts
173
Hepatitis agent cloned and designated hepatitis G virus
174
Hepatitis and community: The current scenario and a roadmap for 2030
175
Hepatitis and death following vaccination with 17D-204 yellow fever vaccine
176
Hepatitis and HIV screening, education, and treatment for adults with serious mental illness
177
Hepatitis Awareness Bus: A Model for Finding Unknown Hepatitis B and C Infections
178
Hepatitis B among homeless and other impoverished US military veterans in residential care in Los Angeles
179
Hepatitis B and C among Patients Infected with Human Immunodeficiency Virus in Isfahan, Iran: Seroprevalence and Associated Factors
180
Hepatitis B and C among thalassemiac patients in Iran: A multicenter study
181
Hepatitis B and C among women with illegal social behavior in Isfahan, Iran: Seroprevalence and associated factors
182
Hepatitis B and C and the Role of Non-specialists on Disease Elimination
183
Hepatitis B and C in HIV-infected patients : Prevalence and prognostic value
184
Hepatitis B and C infection in first-time blood donors in Karachi – a possible subgroup for sentinel surveillance
185
Hepatitis B and C Infections Among Pediatric Patients with Sickle Cell Disease at a Tertiary Hospital in Nigeria
186
Hepatitis B and C Infections and Different Genotypes of HCV Among Sickle Cell Anemia Patients in Ahvaz, South-Western Iran
187
Hepatitis B and C Infections in Hamadan Province during 2004-2009
188
Hepatitis B and C knowledge among Saudi dental patients
189
Hepatitis B and C viral infection: prevalence, knowledge, attitude and practice among barbers and clients in Gharbia governorate, Egypt
190
Hepatitis B and C Viral Infection: Prevalence, Knowledge, Attitude, Practice, and Occupational Exposure among Healthcare Workers of Jimma University Medical Center, Southwest Ethiopia
191
Hepatitis B and C viral infections in chronic liver disease: a populationbased study in Qatar
192
Hepatitis B and C virus hepatocarcinogenesis: Lessons learned and future challenges
193
Hepatitis B and C virus infection and the risk of atherosclerosis in a general population
194
Hepatitis B and C: An alarming situation in Southern part of Khyber Pakhtunkhwa, Pakistan
195
Hepatitis B and C: Prevention is better than cure
196
Hepatitis B and health-care workers
197
Hepatitis B and health-care workers
198
Hepatitis B and health-care workers
199
Hepatitis B and health-care workers
200
Hepatitis B and Hepatitis C in Patients with Inherited Disorders of Hemoglobin in Sistan and Baluchistan Province, Iran
201
Hepatitis B and Hepatitis C Seroprevalence in the Center of Sanliurfa Province From Southeastern Anatolia Region and Related Risk Factors
202
Hepatitis B and hepatitis C virus prevalence among dialysis patients in Bahrain and Saudi Arabia: A survey by serologic and molecular methods
203
Hepatitis B- and Hepatitis C-Related Hepatocellular Carcinomas in the United States: Similarities and Differences
204
Hepatitis B and HIV co-infection is still treated using lamivudine-only antiretroviral therapy combination in Uganda
205
Hepatitis B and its Relationship With Oxidative Stress
206
Hepatitis B associated liver failure following bone marrow transplantation
207
Hepatitis B Awareness and Knowledge in Asian Communities in British Columbia
208
Hepatitis B Birth Dose among Children in District 2 Hospital, Ho Chi Minh City, Vietnam: Prevalence and Associated Factors
209
Hepatitis B booster vaccination for healthcare workers
210
Hepatitis B Core Antibody ImmunoglobulinMin Blood Donors With a History of Hepatitis B Virus Infection
211
HEPATITIS B e ANTIGEN AND THE RISK OF HEPATOCELLULAR CARCINOMA
212
Hepatitis B e Antigen-Negative Chronic Hepatitis B
213
Hepatitis B envelope protein mutants
214
Hepatitis B epidemiology and cultural practices in Amerindian populations of Amazonia: The Tupí-Mondé and the Xavánte from Brazil
215
Hepatitis B genotypes and the response to interferon therapy
216
Hepatitis B Genotypes in Iran
217
Hepatitis B genotypes in patients with acute hepatitis B virus infection
218
Hepatitis B Immune Globulin in Liver Transplantation Prophylaxis: An Update
219
Hepatitis B immunisation in chronically transfused recipients
220
Hepatitis B immunisation in Singapore
221
Hepatitis B Immunization in Health Care Workers: Needs and Opportunities
222
Hepatitis B immunization in postpartum women
223
Hepatitis B in a high prevalence New Zealand population: A mathematical model applied to infection control policy
224
Hepatitis B in China
225
Hepatitis B infection among Asian American Pacific Islanders in the Rocky Mountain area
226
Hepatitis B Infection among Korean Americans in Colorado: Evidence of the Need for Serologic Testing and Vaccination
227
Hepatitis B infection among Nigerian children admitted to a children’s emergency room
228
Hepatitis B Infection among Patients Receiving Chronic Hemodialysis at the Royal Medical Services in Jordan
229
Hepatitis B Infection during Renal Replacement Therapy
230
Hepatitis B infection in Eastern Indian families: Need for screening of adult siblings and mothers of adult index cases
231
Hepatitis B infection in Eastern Mediterranean Region: challenges and the way forward
232
Hepatitis B Infection in Hemodialysis Patients in Tehran Province, Iran
233
Hepatitis B infection is highly endemic in Uganda: findings from a national serosurvey
234
Hepatitis B infection: Pathogenesis and management
235
Hepatitis B Infection: Prevalence and Response to Vaccination among Health Care Workers in Babol, Northern Iran
236
Hepatitis B is a Serious Health Problem in Some Parts of Iran; Sistan and Baluchestan Province
237
Hepatitis B Knowledge Among Healthy Volunteers in Duhok City, Kurdistan Region, Iraq
238
Hepatitis B Knowledge Among Iranian Adolescents: A National Survey
239
Hepatitis B or hepatitis C and human immunodeficiency virus infection
240
Hepatitis B pregenomic RNA splicing—The products, the regulatory mechanisms and its biological significance
241
Hepatitis B prevalence among workers in Turkey at low risk for hepatitis B exposure
242
Hepatitis B Prevention Education and Afghan Immigrant Students
243
Hepatitis B reactivation after lamivudine
244
Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review
245
Hepatitis B Recurrence After Liver Transplantation: A Single Center Experiences and Review the Literature
246
Hepatitis B resistance in Iran
247
Hepatitis B Seroconversion Rate After Primary Immunization Series with Newly Introduced Pentavalent Vaccine: A Report of Local Study in Alborz Province, Iran, 2016
248
Hepatitis B seromarkers, hepatitis C antibody, and risk behaviors in married couples, a bordered province of western Thailand
249
Hepatitis B Seroprevalence and Risk Factors in Adult Population of Chaharmahal and Bakhtiari Province in 2013
250
Hepatitis B Seroprevalence and the Relationship Between Being Hepatitis B Vaccinated and Infected with Social Determinants of Health: Manisa, 2014
251
Hepatitis B Splice-Generated Protein Antibodies in Syrian Chronic Hepatitis B Patients: Incidence and Significance
252
Hepatitis B Stigma and Knowledge among Vietnamese in Ho Chi Minh City and Chicago
253
Hepatitis B surface antibody purification with hepatitis B surface antibody imprinted poly(hydroxyethyl methacrylate-N-methacryloyl-l-tyrosine methyl ester) particles
254
Hepatitis B surface antibody response of household contacts of hepatitis B virus carriers in Palestine
255
Hepatitis B Surface Antigen and Viral DNA Detection and Prevalence in Nigeria
256
Hepatitis B surface antigen carrier rate in unvaccinated and vaccinated children with thalassaemia major at Bahawal Victoria Hospital, Bahawalpur, Pakistan
257
HEPATITIS B SURFACE ANTIGEN DISAPPEARANCE AND HEPATITIS B SURFACE ANTIGEN SUBTYPE: A PROSPECTIVE, LONG-TERM, FOLLOW-UP STUDY OF JAPANESE RESIDENTS OF OKINAWA, JAPAN WITH CHRONIC HEPATITIS B VIRUS INFECTION
258
Hepatitis B Surface Antigen Prevalence among Pregnant Women in Rafsanjan City, Iran, 2003
259
Hepatitis B surface antigen prevalence in pregnant women: A cross‑sectional survey in Iran
260
Hepatitis B surface antigen, hepatitis C and HIV antibodies in a low-risk blood donor group, Nigeria
261
Hepatitis B Surface Antigen, Hepatitis C Virus Antibody, Body Mass Index, and Alcohol Drinking among Workers with Elevated Serum Alanine Aminotransferase
262
Hepatitis B surface antigenemia (HBsAg) among pregnant women in southern Nigeria
263
Hepatitis B surface antigen-negative, but HBV DNA-positive patients in Bangladesh
264
Hepatitis B testing among Vietnamese American men
265
Hepatitis B transmission from contaminated cryopreservation tank
266
Hepatitis B vaccination after liver transplantation as a strategy to discontinue prophylaxis with hepatitis B immune globulin
267
Hepatitis B vaccination among primary health care workers in Northwest Pakistan
268
HEPATITIS B VACCINATION AND INFANTILE IDIOPATHIC THROMBOCYTOPENIC PURPURA
269
Hepatitis B vaccination coverage among Iranian children aged 15–26 months in 2006
270
Hepatitis B Vaccination Coverage Among Iranian Medical Students and Nursing Staff
271
Hepatitis B Vaccination Coverage and Its Associated Factors in Nurses of Imam Reza (AS) Hospital in Kermanshah
272
Hepatitis B Vaccination Coverage and Sharp Injuries Among Healthcare Workers in Hamadan, Iran
273
Hepatitis B vaccination coverage in medical students at a medical college of Mirpurkhas
274
Hepatitis B Vaccination Coverage, HBS-Ab Level and its Related Factors among Dentistry and Medical Students
275
Hepatitis B Vaccination Efficacy in Iranian Healthcare Workers: A Meta-Analysis Study
276
Hepatitis B vaccination follow-up
277
Hepatitis B Vaccination in Bangladesh: a Suggestion Based on Current Evidence
278
Hepatitis B Vaccination in Chronic Kidney Disease: Review of Evidence in Non-Dialyzed Patients
279
Hepatitis B vaccination in correctional health care workers
280
Hepatitis B vaccination in correctional health care workers
281
Hepatitis B vaccination of babies in Melanesia
282
Hepatitis B vaccination of health care workers in Saudi Arabia
283
Hepatitis B vaccination program at a New York City hospital: Seroprevalence, seroconversion, and declination, ,
284
Hepatitis B Vaccination Reliability in Celiac Disease
285
Hepatitis B Vaccination Status in Dental Practitioners: Local Horrifying Report, National Considerable Issue, and Global Health Impact
286
Hepatitis B vaccination strategy for newborn babies
287
Hepatitis B Vaccination: Needs a Revision
288
Hepatitis B vaccination: to boost or not to boost?
289
Hepatitis B Vaccine Acceptability among Nurses: A Theory Based Conceptualization
290
Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy
291
Hepatitis B vaccine booster dose: Low-dose recombinant hepatitis B vaccines as a booster dose,
292
Hepatitis B vaccine boosting among young healthy adults
293
Hepatitis B vaccine boosting: the debate continues
294
Hepatitis B Vaccine Coverage and the Immune Response in Children under ten years old in Sana’a, Yemen
295
Hepatitis B vaccine in patients on haemodialysis
296
Hepatitis B vaccine, hepatitis C virus infection, and haemodialysis
297
Hepatitis B Vaccine: Immunity, Efficacy and Types.
298
Hepatitis B Viral DNA Among HBs Antigen Negative Healthy Blood Donors
299
Hepatitis B viral genotypes and lamivudine resistance
300
Hepatitis B Viral Markers in Surface Antigen Negative Blood Donors: The Need to Look Beyond Antibody Negativity
301
Hepatitis B viral resistance: mechanisms and diagnosis
302
Hepatitis B viral X protein interacts with tumor suppressor adenomatous polyposis coli to activate Wnt/β-catenin signaling
303
Hepatitis B Virus (HBV) and Occult Hepatitis B Virus (OBI) in Hemodialysis Patients: An Epidemiological Observational Study in Kerman, Iran (2022-2023)
304
Hepatitis B virus (HBV) DNA assays (methods and practical use) and viral kinetics
305
Hepatitis B Virus (HBV) Infection among Pregnant Women in Makurdi, Nigeria
306
Hepatitis B virus (HBV) vaccine-induced escape mutants of HBV S gene among children from Qidong area, China
307
Hepatitis B Virus / Human Immunodeficiency Virus Co-Infection and Its Hepatocarcinogenic Potential in Sub-Saharan Black Africans
308
Hepatitis B virus among maintainence haemodialysis patients: A report from Karachi, Pakistan
309
Hepatitis B virus among schoolchildren in an endemic area in Egypt over a decade: Impact of hepatitis B vaccine
310
Hepatitis B virus and celiac disease
311
Hepatitis B Virus and Cytomegalovirus Infections Disrupt Sperm Parameters in Males through Decreasing Mitochondrial Membrane Potential: A Case-control Study
312
Hepatitis B virus and hepatocellular carcinoma
313
Hepatitis B virus and HIV infection among patients with primary hepatocellular carcinoma in Kampala, Uganda
314
Hepatitis B virus and host factors
315
Hepatitis B Virus and Malaria Co-infection Causing Significant Changes in Hematological and Liver Function Indices in a Cohort of Subjects in Ilorin, Nigeria
316
Hepatitis B Virus Antibody Levels in High-Risk Health Care Workers
317
Hepatitis B virus clearance by transplantation of bone marrow from hepatitis B immunised donor
318
Hepatitis B Virus Complications of Pregnancy After Kidney Transplantation
319
Hepatitis B Virus Core Promoter Mutations in Patients With Chronic Hepatitis B and Hepatocellular Carcinoma in Bucharest, Romania
320
Hepatitis B virus DNA in sera and liver tissue of HBsAg negative patients with chronic hepatitis C
321
Hepatitis B Virus DNA is Absent in Lebanese Blood Donors Who Are Positive for Both Anti-Hbc and Anti-Hbs Antibodies
322
Hepatitis B virus DNA level Among the Seropositive Afghan Immigrants, Southern Iran
323
Hepatitis B virus DNA level as predictor of response to therapy with interferon-alpha-2b (PDferon) in chronic hepatitis B infection
324
Hepatitis B virus E antigen but not HBV core is presented to specific CD4+ T cells via the endogenous antigen processing pathway
325
Hepatitis B virus enhances interleukin-27 expression both in vivo and in vitro
326
Hepatitis B virus enhances transduction of human hepatocytes by SV40-based vectors
327
Hepatitis B virus enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity by increasing TRAIL-R1/death receptor 4 expression
328
Hepatitis B virus genetic diversity in Latin America
329
Hepatitis B virus genetic variability and evolution
330
Hepatitis B Virus Genome Asymmetry in Hepatocellular Carcinoma
331
Hepatitis B Virus Genotype B and High Expression of Interferon Alpha Receptor β Subunit are Associated With Better Response to Pegylated Interferon Alpha 2a in Chinese Patients With Chronic Hepatitis B Infection
332
Hepatitis B Virus Genotype G Infection in a Turkish Patient Undergoing Hemodialysis Therapy
333
Hepatitis B virus genotypes and extrahepatic manifestations
334
Hepatitis B Virus Genotypes Distribution with HBsAg Positive in the North of Iran (Mazandaran) During 2011-2014
335
Hepatitis B Virus Genotypes in Eastern Azerbaijan, Northwest Iran
336
Hepatitis B virus genotypes, core gene variability and ethnicity in the Pacific region
337
Hepatitis B Virus Genotypes, Epidemiological Characteristics, and Clinical Presentation of HBV Chronic Infection in Immigrant Populations Living in Southern Italy
338
Hepatitis B Virus Genotyping Among Chronic Hepatitis B Individuals With Resistance to Lamivudine in Shahrekord, Iran
339
Hepatitis B Virus Genotyping Among Chronic Hepatitis B Individuals With Resistance to Lamivudine in Shahrekord, Iran
340
Hepatitis B virus Genotyping Among Patients With Cirrhosis
341
Hepatitis B Virus Immunity Status and Booster Dose Efficacy in Health Sciences Students: An Interventional Study
342
Hepatitis B virus in cervicovaginal lavage samples of pregnant women in Gorgan city, north of Iran
343
Hepatitis B virus induced hepatocellular carcinoma
344
Hepatitis B Virus Infection among Health Colleges’ Students in Aseer Region, Southwestern Saudi Arabia
345
Hepatitis B virus infection among staff in three hospitals in Khartoum, Sudan, 2006–07
346
Hepatitis B Virus Infection and Exposure Among Foreign-Born Asian Americans in the U.S.
347
Hepatitis B Virus Infection and Oral Lichen Planus: A Report from Northeast of Iran
348
Hepatitis B Virus Infection and Oral Lichen Planus: A Report from Northeast of Iran
349
Hepatitis B virus infection contributes to oxidative stress in a population exposed to aflatoxin B1 and high-risk for hepatocellular carcinoma
350
Hepatitis B Virus Infection during Pregnancy: Transmission and Prevention
351
Hepatitis B Virus Infection Flare Induced Acute-on-chronic Liver Failure After COVID-19 Vaccination: A Case Report
352
HEPATITIS B VIRUS INFECTION IN AN ANTI-HBC NEGATIVE PATIENT: A CASE REPORT
353
Hepatitis B virus infection in Iran
354
Hepatitis B Virus Infection in Iran: A Systematic Review
355
Hepatitis B Virus Infection in Iran: Current Knowledge, Future Plans
356
Hepatitis B Virus Infection in Iranian Hemodialysis Patients A Systematic Review and Meta-Analysis
357
Hepatitis B virus infection in lymphatic tissues in inactive hepatitis B carriers
358
Hepatitis B Virus Infection in Patients with Blood Disorders: A Concise Review in Pediatric S
359
Hepatitis B Virus Infection in the General Population of Iran: An Updated Systematic Review and Meta-Analysis
360
Hepatitis B Virus Infection in Vaccinated Children and Adolescents with HBsAg-positive Parents: Is Routine Vaccination Sufficient?
361
Hepatitis B Virus Infection Serology and the Associated Risk Factors Among Patients With HIV in Shiraz, Iran
362
Hepatitis B virus infection without immunological markers after open-heart surgery
363
Hepatitis B virus infection: Current status
364
Hepatitis B Virus Infection; A Vanishing Disease in Iranian Children
365
Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis
366
Hepatitis B virus large surface protein: function and fame
367
Hepatitis B virus mutants and efficacy of vaccination
368
Hepatitis B virus mutants and efficacy of vaccination
369
Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation
370
Hepatitis B virus precore mutants in serum and liver of Southern African Blacks with hepatocellular carcinoma
371
Hepatitis B Virus PreS Variant and Hepatocellular Carcinoma
372
Hepatitis B Virus preS2 Domain Promotes Angiogenesis in Hepatocellular Carcinoma via Transcriptional Activation of VEGFA Promoter
373
Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response
374
Hepatitis B Virus Reactivation Potential Risk Factors in Hepatocellular Carcinoma via Transcatheter Arterial Chemoembolization: A Retrospective Research
375
Hepatitis B virus replication and viral antigen synthesis in hepatocyte lines derived from normal human liver
376
Hepatitis B virus resistance to antivirals: clinical implications and management
377
Hepatitis B Virus Screening and Real Life Data in Patients with Solid Tumor Receiving Chemotherapy
378
Hepatitis B virus sequence changes evolving in liver transplant recipients with fulminant hepatitis
379
Hepatitis B virus seropositivity is not associated with increased risk of carotid atherosclerosis in Taiwanese
380
Hepatitis B Virus Should not be Forget in Health Care Worker
381
Hepatitis B virus subtypes and lamivudine resistance
382
Hepatitis B Virus Surface Antigen (HBsAg) Mutations Are Rare but Clustered in Immune Epitopes in Chronic Carriers from Sistan-Balouchestan Province, Iran
383
Hepatitis B Virus Surface Antigen Variants Clustered Within Immune Epitopes in Chronic Hepatitis B Carriers from Hormozgan Province, South of Iran
384
Hepatitis B virus transmission and hepatocarcinogenesis: a 9 year retrospective cohort of 13 676 relatives with hepatocellular carcinoma
385
Hepatitis B Virus Vaccination in Hemodialysis Patients: A Necessity for Individualizing of Immunization?
386
Hepatitis B Virus Vaccine immune response in Egyptian children 15-17 years after primary immunization; should we provide a booster dose?
387
Hepatitis B virus viral dynamics: effects of drug dose and baseline alanine aminotransferase
388
Hepatitis B virus X antigen and aflatoxin B1 synergistically cause hepatitis, steatosis and liver hyperplasia in transgenic zebrafish
389
Hepatitis B virus X gene is implicated in liver carcinogenesis
390
Hepatitis B virus X mediates podocyte pyroptosis by regulating the ROS/NLRP3 signaling pathway in hepatitis B virus-associated glomerulonephritis
391
Hepatitis B virus X protein (HBx) activates ATF6 and IRE1-XBP1 pathways of unfolded protein response
392
Hepatitis B virus X protein induced expression of interleukin 18 (IL-18): a potential mechanism for liver injury caused by hepatitis B virus (HBV) infection
393
Hepatitis B virus X protein induces apoptosis in hepatoma cells through inhibiting Bcl-xL expression
394
Hepatitis B virus X protein interacts with NF-KB inhibitors
395
Hepatitis B virus X protein overcomes stress-induced premature senescence by repressing p16INK4a expression via DNA methylation
396
Hepatitis B virus X protein promotes cell migration by inducing matrix metalloproteinase-3
397
Hepatitis B virus X protein stimulates the Hedgehog–Gli activation through protein stabilization and nuclear localization of Gli1 in liver cancer cells
398
Hepatitis B Virus X Protein Up-Regulates AKR1C1 Expression Through Nuclear Factor-Y in Human Hepatocarcinoma Cells
399
Hepatitis B virus YMDD-motif mutations with emergence of lamivudine-resistant mutants: a threat to recovery
400
Hepatitis B Virus, Hepatitis C Virus Markers and Serum Alanine Amino-Transferase (ALT) Levels, in a Young Adult Population of Sylhet District
401
Hepatitis B Virus-associated Glomerulonephritis
402
Hepatitis B Virus-associated Nephropathy An International Data Analysis
403
Hepatitis B viruses and cancerogenesis
404
Hepatitis B viruses: Reverse transcription a different way
405
Hepatitis B virus-induced hepatocellular carcinoma
406
Hepatitis B virus-infected cells can be eliminated by the cytotoxic T cell-mediated immune reaction. Fas ligand, recently detected on the surface of cytotoxic T cell, is thought to induce cells to apoptosis by adhering to Fas antigen. Aims/Methods: To eva
407
Hepatitis B virus-related vasculitis manifesting as severe peripheral neuropathy following influenza vaccination
408
Hepatitis B, C virus co-infection and behavioral risks in HIV-positive patients in southern Iran
409
Hepatitis B, Hepatitis C and HIV seroprevalence in critically ill emergency medicine department patients in a tertiary inner city hospital in Istanbul, Turkey
410
Hepatitis B, Hepatitis C and Human Immunodeficiency Virus Seropositivity Among Children in Kabul, Afghanistan: A Cross-Sectional Study
411
Hepatitis B, Hepatitis C, and Human Immune deficiency Virus Seroconversion Positivity Rates and Their Potential Risk Factors Among Patients on Maintenance Hemodialysis in Cameroon
412
Hepatitis B, Hepatitis C, and Human Immunodeficiency Virus Infection in Multi-Transfused Thalassemic Patients, Kermanshah, Iran, 2015
413
Hepatitis B, Hepatitis C, and Human Immunodeficiency Virus Infection in Multi-Transfused Thalassemic Patients, Kermanshah, Iran, 2015
414
Hepatitis B, hepatitis C, HIV, and VDRL seroprevalence of blood donors in Mersin, Turkey*
415
Hepatitis B: Epidemiology and prevalence in Iran, during 2002-2014
416
Hepatitis B: Knowledge, Vaccine Situation and Seroconversion of Dentistry Students of a Public University
417
Hepatitis B: Reflections on the current approach to antiviral therapy
418
Hepatitis BMarkers in Isfahan, Central Iran: APopulation-Based Study
419
Hepatitis B-Related Concerns and Anxieties Among People With Chronic Hepatitis B in Australia
420
Hepatitis C (HCV) Viremic Rate and its Correlation to Demographic Factors among HCV Confirmed Iranian Blood Donors
421
Hepatitis C among Hemodialysis Patients: A Review on Epidemiologic, Diagnostic, and Therapeutic Features
422
Hepatitis C among Hemodialysis Patients: Impact of Strict Adherence to Universal Precautions
423
Hepatitis C among Intravenous Drug Users in Isfahan, Iran: A Study of Seroprevalence and Risk Factors
424
HEPATITIS C AMONG YOUNG MALE OFFENDERS ADMITTED TO THE CENTRAL JAIL, LAHORE
425
Hepatitis C and alcohol
426
Hepatitis C and B-cell lymphoma: the hemato-hepatologist linkage
427
Hepatitis C and B-cell non-Hodgkin’s lymphoma: a geographicallyvariable association?
428
Hepatitis C and blood transfusion among children attending the Sickle Cell Clinic at Mulago Hospital, Uganda
429
Hepatitis C and Depression
430
Hepatitis C and G Virus Infection Prevalence Among Hemodialysis Patients and Associated Risk Factors in the Hormozgan Province of Southern Iran
431
Hepatitis C and hepatitis B seroprevalence and associated risk factors in hemodialysis patients in Guilan province, north of Iran
432
Hepatitis C and Hepatitis B Virus Infection: Epidemiology and Risk Factors in a Large Cohort of Pregnant Women in Lorestan, West of Iran
433
Hepatitis C and HIV infection: biological, clinical, and therapeutic implications
434
Hepatitis C and hospital outcomes in patients admitted with alcohol-related problems
435
Hepatitis C and liver transplantation
436
Hepatitis C and pulmonary fibrosis
437
Hepatitis C and renal failure
438
Hepatitis C and Steatosis
439
Hepatitis C and Teens
440
Hepatitis C and Teens
441
Hepatitis C and the correctional population
442
Hepatitis C and the heart: to beat or not to beat
443
Hepatitis C and thyroid autoimmunity: is there a link?
444
Hepatitis C and Why the Treatment is Needed Now? The Summary Report From the Cross-Border Symposium of the 5th Tehran Hepatitis Congress May 2013
445
Hepatitis C at work place: A survey of Occupational Health and Safety Knowledge and Practice in Beauty Therapy Industry
446
Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era
447
Hepatitis C detection
448
Hepatitis C detection
449
Hepatitis C genotype and associated risks factors of patients at University Kebangsaan Malaysia Medical Centre
450
Hepatitis C Genotypes Distribution in Intravenous Drug Users in Tehran
451
Hepatitis C Genotypes in Hemophilia Patients in Iran
452
Hepatitis C Genotypes in Hemophilia Patients in Iran
453
Hepatitis C impairs survival following liver transplantation irrespective of concomitant hepatocellular carcinoma
454
HEPATITIS C IN A COMMUNITY IN UPPER EGYPT: I. CROSS-SECTIONAL SURVEY
455
Hepatitis C in Australia: Impact of a Mass Media Campaign Original Research Article
456
Hepatitis C in haemophilia patients in the Netherlands
457
Hepatitis C in Hemodialysis Centers of Golestan Province, Northeast of Iran (2005)
458
Hepatitis C in hemodialysis patients needs more attention for control and review the risk factors
459
Hepatitis C in Iran. How Extensive of a Problem Is It?
460
Hepatitis C in Pakistan: A Review of Available Data
461
HEPATITIS C IN PERU: RISK FACTORS FOR INFECTION, POTENTIAL IATROGENIC TRANSMISSION, AND GENOTYPE DISTRIBUTION
462
Hepatitis C in State Correctional Facilities
463
Hepatitis C in the Eastern Mediterranean Region
464
Hepatitis C in the patient with human immunodeficiency virus infection
465
Hepatitis C Infection Among HIV-Positive Injection Drug Users and Non-Injection-Drug Users in Tajikistan
466
Hepatitis C infection and autoimmune hemolytic anemia in a patient with colon B-cell non-hodgkin lymphoma: a case report
467
Hepatitis C infection and polymyositis
468
Hepatitis C infection and risk of diabetes: A systematic review and meta-analysis
469
Hepatitis C infection from anti-D immunoglobulin
470
Hepatitis C Infection in Egyptian Psoriatic Patients: Prevalence and Correlation with Severity of Disease
471
Hepatitis C infection in Iran; A review article
472
Hepatitis C Infection in the General Population of Iran: A Systematic Review
473
Hepatitis C infection increases the risk of new-onset diabetes after transplantation in liver allograft recipients
474
Hepatitis C infection is characterized by a high incidence of liver cirrhosis, frequently requiring liver transplantation. After orthotopic liver transplantation, recurrence of hepatitis C virus infection is common, but often difficult to differentiate fr
475
Hepatitis C infection: a review on epidemiology and management of occupational exposure in health care workers for general physicians working in Iranian health network setting
476
Hepatitis C infection: a review on epidemiology and management of occupational exposure in health care workers for general physicians working in Iranian health network setting
477
Hepatitis C is associated with perturbation of intrahepatic myeloid and plasmacytoid dendritic cell function
478
Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse
479
Hepatitis C NS3 helicase unwinds RNA in leaps and bounds
480
Hepatitis C NS3 protease inhibition by peptidyl-α-ketoamide inhibitors: kinetic mechanism and structure
481
Hepatitis C NS5B polymerase inhibitors: 4,4-Dialkyl-1-hydroxy-3-oxo-3,4-dihydronaphthalene-3-yl benzothiadiazine derivatives
482
Hepatitis C outbreak astounds Spain
483
Hepatitis C Prevalence and Risk Factors in the Northern Alberta Dialysis Population
484
Hepatitis C Prevalence and Risk Factors in the Northern Alberta Dialysis Population
485
Hepatitis C Rapid Point-of-Care Testing and Laboratory-based Non-invasive Assessment of Liver Fibrosis among Drug Abusers: An Experience from Iran
486
Hepatitis C seropositivity in patients with acute and chronic urticaria
487
Hepatitis C seroprevalence among intravenous drug users in Tehran
488
Hepatitis C seroprevalence among newly incarcerated inmates in the Texas correctional system
489
Hepatitis C therapy in treatment-naïve patients
490
Hepatitis C transmission associated with intravenous immunoglobulins
491
Hepatitis C transmission by cosmetic tattooing in women
492
Hepatitis C Treatment Among People Who Use Drugs in an Office-Based Opioid Treatment Program Versus a Syringe Exchange Program: A Real-World Prospective Clinical Trial
493
Hepatitis C treatment update
494
Hepatitis C Viral Heterogeneity Based on Core Gene and an Attempt to Design Small Interfering RNA Against Strains Resistant to Interferon in Rawalpindi, Pakistan
495
Hepatitis C viral IRES inhibition by phenazine and phenazine-like molecules
496
Hepatitis C viral kinetics in difficult to treat patients receiving high dose interferon and ribavirin
497
Hepatitis C viral kinetics in plasma and peripheral blood mononuclear cells during pegylated interferon-α2a/ribavirin therapy
498
Hepatitis C viral life cycle
499
Hepatitis C virus
500
Hepatitis C Virus - Related Hepatocellular Carcinoma in the Era of Direct - Acting Antiviral Agents
501
Hepatitis C Virus (HCV) “A Possible Independent Risk Factor” for Coronary Artery Disease
502
Hepatitis C virus (HCV) E1 and E2 protein regions that specifically bind to HepG2 cells
503
Hepatitis C virus (HCV) genotype 1B infection is associated with a high incidence of graft cirrhosis after liver transplantation (OLT)
504
Hepatitis C virus (HCV) genotypes in Spanish patients with HCV infection: relationship between HCV genotype 1b, cirrhosis and hepatocellular carcinoma
505
Hepatitis C virus (HCV) hypervariable region 1 complexity does not correlate with severity of liver disease, HCV type, viral load or duration of infection
506
Hepatitis C virus (HCV) infection in hemodialysis patients in the south of Jordan
507
Hepatitis C virus (HCV) Infection Rate among Seronegative Hemodialysis Patients Screened by Two Methods; HCV Core Antigen and Polymerase Chain Reaction
508
Hepatitis C Virus (HCV) Prevalence in Special Populations and Associated Risk Factors: A Report From a Tertiary Hospital
509
Hepatitis C virus (HCV) status in newborns born to HCV positive women performing intracytoplasmic sperm injection
510
Hepatitis C virus (HCV)-driven stimulation of subfamily-restricted natural IgM antibodies in mixed cryoglobulinemia
511
Hepatitis C virus (HCV)-infection and oral lichen planus
512
Hepatitis C Virus and Associated Risk Factors among Prison Inmates with History of Drug Injection in Isfahan, Iran
513
Hepatitis C virus and blood transfusion: past and present risks
514
Hepatitis C virus and hepatocellular carcinoma
515
Hepatitis c virus and human immunodeficiency virus: clinical issues in coinfection
516
Hepatitis C Virus and Human Immunodeficiency Virus-I (HIV) Co-Infection in Children in Benin City, Nigeria.
517
Hepatitis C virus and kidney disease
518
Hepatitis C Virus and Lichen Planus: The Real Association
519
Hepatitis C virus and liver steatosis: when fat is not beautiful
520
Hepatitis C Virus and Vaccine Development
521
Hepatitis C Virus Antibodies and Vitiligo Disease
522
Hepatitis C Virus Antibody Positive Cases in Multitransfused Thalassemic Patients in South of Iran
523
Hepatitis C virus antibody, viral RNA and genotypes in leprous patients in Japan
524
Hepatitis C Virus as a Multifaceted Disease: A Simple and Updated Approach for Extrahepatic Manifestations of Hepatitis C Virus Infection
525
Hepatitis C virus assembly: When fat makes it easier
526
Hepatitis C Virus Capsid Protein and Intracellular Lipids Interplay and Its Association With Hepatic Steatosis
527
Hepatitis C virus challenges AIDS associated viruses at the transfusion crossings: the place and time for a second trial
528
Hepatitis C virus clearance improves quality of life
529
Hepatitis C virus Core Antigen as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon α-2b plus ribavirin
530
Hepatitis C Virus Core Antigen as an Alternative to RNA in the Assessment of Response to Treatment with Direct-acting Oral Antivirals
531
Hepatitis C virus core protein downregulates E-cadherin expression via activation of DNA methyltransferase 1 and 3b
532
Hepatitis C virus core protein exerts an inhibitory effect on suppressor of cytokine signaling (SOCS)-1 gene expression
533
Hepatitis C virus core protein impairs in vitro priming of specific T cell responses by dendritic cells and hepatocytes
534
Hepatitis C virus core protein inhibits human immunodeficiency virus type 1 replication
535
Hepatitis C virus Core protein overcomes all-trans retinoic acid-induced cell growth arrest by inhibiting retinoic acid receptor-β2 expression via DNA methylation
536
Hepatitis C virus Core protein overcomes stress-induced premature senescence by down-regulating p16 expression via DNA methylation
537
Hepatitis C virus core protein potentiates c-Jun N-terminal kinase activation through a signaling complex involving TRADD and TRAF2
538
Hepatitis C virus Core protein stimulates cell growth by down-regulating p16 expression via DNA methylation
539
Hepatitis C Virus Core Protein: An Update on Its Molecular Biology, Cellular Functions and Clinical Implications
540
Hepatitis C Virus Cryoglobulinemia and non-Hodgkin Lymphoma
541
Hepatitis C virus density heterogeneity and viral titre in acute and chronic infection: a comparison of immunodeficient and immunocompetent patients
542
Hepatitis C virus E2 links soluble human CD81 and SR-B1 protein
543
Hepatitis C virus eradication associated with hepatitis B virus superinfection and development of a hepatitis B virus specific T cell response
544
Hepatitis C virus genetic variability in patients undergoing antiviral therapy
545
Hepatitis C virus genotype 1 associated with massive steatosis of the liver and hypo-β-lipoproteinemia
546
Hepatitis C Virus Genotype Distribution in Shiraz, Southern Iran
547
Hepatitis C Virus Genotypes and Association With Viral Load in Yazd, Central Province of Iran
548
Hepatitis C virus genotypes and quasispecies
549
Hepatitis C virus genotypes and subtypes in patients with hepatitis C, with and without cryoglobulinemia
550
HEPATITIS C VIRUS GENOTYPES IN A NORTHEASTERN AREA OF BRAZIL
551
Hepatitis C virus genotypes in Adana and Antakya regions of Turkey
552
HEPATITIS C VIRUS GENOTYPES IN BAHAWALPUR
553
Hepatitis C virus genotypes in elderly patients with chronic hepatitis C
554
HEPATITIS C VIRUS GENOTYPES IN IRAQ
555
Hepatitis C Virus Genotypes in Patients Referred to Educational Hospitals in Zahedan (2009 ‒ 2013)
556
Hepatitis C virus Genotypes in Patients with End-Stage Renal Disease in East Azerbaijan, Iran
557
Hepatitis C virus genotyping by means of 5′-UR/core line probe assays and molecular analysis of untypeable samples
558
Hepatitis C Virus Genotyping by Melting Curve Analysis in West Azerbaijan, Northwest of Iran
559
Hepatitis C virus in blood donation
560
Hepatitis C virus in breast milk
561
Hepatitis C virus in elderly patients with chronic liver diseases
562
HEPATITIS C VIRUS IN IRAN: EPIDEMIOLOGY OF AN EMERGING INFECTION
563
Hepatitis C virus in Iran; transmission routes, growth in 3a genotype distribution, and lack of liver marker relation with genotypes
564
Hepatitis C Virus in North Africa: An Emerging Threat
565
Hepatitis C virus in people with HIV infection
566
Hepatitis C virus in people with HIV infection
567
Hepatitis C virus in saliva of haemophiliac patients attending an oral surgery unit
568
Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C
569
Hepatitis C virus infection affects the brain—evidence from psychometric studies and magnetic resonance spectroscopy
570
Hepatitis C virus infection among institutionalised psychiatric patients: a regression analysis of indicators of risk
571
Hepatitis C virus infection among multi-transfused patients and personnel in haemodialysis units in central Islamic Republic of Iran
572
Hepatitis C virus infection among paediatric patients attending University of Assiut Hospital, Egypt
573
Hepatitis C virus infection among patients on hemodialysis: A report from a single center in Iran
574
Hepatitis C Virus Infection among Teaching Hospital Patients in Kano, Nigeria: A Retrospective Study
575
Hepatitis C virus infection and alanine transaminase levels in the general population: a survey in a southern Italian town
576
Hepatitis C virus infection and autoimmune thrombocytopenic purpura
577
Hepatitis C Virus Infection and Chronic Obstructive Pulmonary Disease
578
Hepatitis C virus infection and cryoglobulinemia
579
Hepatitis C virus infection and genotypes in blood donors
580
Hepatitis C Virus Infection and HCV Genotypes of Hemodialysis Patients
581
Hepatitis C Virus Infection and Kidney Transplantation A Review for Clinicians
582
Hepatitis C virus infection and lymphoproliferative diseases: Prospective study on 1,576 patients in France
583
Hepatitis C virus infection and primary Sjögrenʹs Syndrome: A clinical and serologic description of 9 patients
584
Hepatitis C virus infection and risk factors in health-care workers at Ain Shams University Hospitals, Cairo, Egypt
585
Hepatitis C Virus Infection Complicated by Kidney Disease
586
Hepatitis C Virus Infection in Blood Donors: An Emerging Risk to Transfusion Services
587
Hepatitis C virus infection in children
588
Hepatitis C virus infection in dialysis centers of Tabriz, Iran: a multicenter study
589
Hepatitis C virus infection in dialysis patients
590
Hepatitis C virus infection in Eastern Europe
591
Hepatitis C virus infection in hemodialysis patients in Sudan: Two centers report
592
Hepatitis C Virus Infection in Iran; Viral Spread Routes in General Population and Safety Measures
593
Hepatitis C Virus Infection in Isfahan, Iran: A Review Article
594
Hepatitis C virus infection in nephrology patients
595
Hepatitis C Virus Infection in Non-Hodgkin’s Lymphoma: A Case-ControlStudy
596
HEPATITIS C VIRUS INFECTION IN PATIENTS ON LONG TERM HEMODIALYSIS
597
Hepatitis C Virus Infection in Patients with Hemophilia in Isfahan, Iran
598
Hepatitis C virus infection in renal transplant recipients: epidemiology, clinical impact, serological confirmation and viral replication
599
Hepatitis C virus infection in special groups
600
Hepatitis C virus infection in the development of hepatocellular carcinoma in cirrhosis
601
Hepatitis C virus infection in the United States
602
Hepatitis C virus infection in Western Europe
603
Hepatitis C virus infection manifesting as tubulointerstitial nephritis, cardiomyopathy, and hepatitis
604
Hepatitis C virus infection of salivary gland epithelial cells : Lack of evidence
605
Hepatitis C Virus Infection Trends in Italy
606
Hepatitis C Virus Infection Trends in Italy, 1996–2006
607
Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction
608
Hepatitis C virus infection, mixed cryoglobulinemia and BLyS upregulation: Targeting the infectious trigger, the autoimmune response, or both?
609
Hepatitis C virus infection, tuberculosis, and sexually transmitted diseases
610
Hepatitis C virus infection: co-infection with HIV and HBV
611
Hepatitis C virus infection: Epidemiology, risk factors and prevention strategies in public health in I.R. IRAN
612
Hepatitis C virus infection: quality of life and side effects of treatment
613
Hepatitis C virus infection: when silence is deception
614
Hepatitis C virus infection-associated non-cryoglobulinaemic monoclonal IgMκ gammopathy responsive to interferon-α treatment
615
Hepatitis C Virus Load in Seropositive Liver and Kidney Transplant Recipients by Quantitative Real-Time PCR Before and After Transplantation
616
Hepatitis C virus molecular clones and their replication capacity in vivo and in cell culture
617
Hepatitis C virus NS3 NTPase/Helicase: different stereoselectivity in nucleoside triphosphate utilisation suggests that NTPase and helicase activities are coupled by a nucleotide-dependent rate limiting step
618
Hepatitis C virus NS3 protease inhibitors comprising a novel aromatic P1 moiety Original Research Article
619
Hepatitis C Virus NS3 Protease Requires Its NS4A Cofactor Peptide for Optimal Binding of a Boronic Acid Inhibitor as Shown by NMR Original Research Article
620
Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding
621
Hepatitis C virus NS3-4A serine protease inhibitors: SAR of moiety with improved potency
622
Hepatitis C virus NS3-4A serine protease inhibitors: SAR of new P1 derivatives of SCH 503034
623
Hepatitis C virus NS3-4A serine protease inhibitors: Use of a P2–P1 cyclopropyl alanine combination for improved potency
624
Hepatitis C virus NS5A protein protects against TNF-α mediated apoptotic cell death
625
Hepatitis C Virus NS5B Sequence-Based Genotyping Analysis of Patients From the Sharkia Governorate, Egypt
626
Hepatitis C Virus RNA (HCV-RNA) in Blood Donors and Family Members Seropositive for Anti-HCV Antibodies
627
Hepatitis C virus RNA: Dinucleotide frequencies and cleavage by RNase L
628
Hepatitis C virus RNAs replicating in cell culture
629
Hepatitis C Virus Screening of High-Risk Patients in a Canadian Emergency Department
630
Hepatitis C virus seropositivity, but not hepatitis B virus carrier or seropositivity, associated with increased pulse wave velocity
631
Hepatitis C Virus Seroprevalence and Associated Risk Factors Among Male Drug Injectors in Kermanshah, Iran
632
Hepatitis C Virus Subtype 3a Envelope Protein 1 Binding with Human Leukocyte Antigen Class I Types of Pakistani Population: Candidate Epitopes for Synthetic Peptide Vaccine
633
Hepatitis C Virus Subtype 6a Infection in an Iranian Patient: A Case Report
634
Hepatitis C Virus Subtype 6a Infection in an Iranian Patient: A Case Report
635
Hepatitis C virus transmission by a blood donation negative in nucleic acid amplification tests for viral RNA
636
Hepatitis C virus transmission by intravenous immunoglobulin
637
Hepatitis C virus transmission by monoclonal- purified viral-attenuated factor VIII concentrate
638
Hepatitis C Virus Treatment Revolution: Eastern European Story
639
Hepatitis C Virus Treatment with Sofosbuvir Plus Ribavirin Regimen in Khuzestan Province
640
Hepatitis C virus types 7, 8 and 9 should be classified as type 6 subtypes
641
Hepatitis C virus ultrastructure and morphogenesis.
642
Hepatitis C virus viral recurrence and liver mitochondrial damage after liver transplantation in HIV–HCV co-infected patients
643
Hepatitis C virus, rheumatoid factors, and disease progression
644
Hepatitis C virus, Sjögrenʹs syndrome and B-cell lymphoma: linking infection, autoimmunity and cancer
645
Hepatitis C Virus. Current Studies in Hematology and Blood Transfusion : Edited by Harvey Reesink, 212, S. Karger AG, Basel, DM 290, ISBN 3-8055-5866-X
646
Hepatitis C Virus: The Rising Concerns and Growing Hopes, Report From the HCV Symposium, Fourth Tehran Hepatitis Congress, November 2011, Tehran, Iran
647
Hepatitis C Virus; Its Implication for Endodontists
648
Hepatitis C virus-related arthritis
649
Hepatitis C virus-specific B cell activation: IgG and IgM detection in acute and chronic hepatitis C
650
Hepatitis c virus-specific cytolytic t cell responses after antiviral therapy
651
Hepatitis C Virus-Specific DNA Sequences in Human DNA: Differentiation by Means of Restriction Enzyme Analysis at the DNA Level in Healthy, Anti-HCV-Negative Individuals
652
Hepatitis C virus-specific reactivity of CD4+-lymphocytes in children born from HCV-infected women
653
Hepatitis C with and without dermatological manifestations: comparison of human leukocyte antigen-DR types, circulating T-cell subsets, and relation to disease severity
654
Hepatitis C, ,
655
Hepatitis C, depressive symptoms, viral load, and therapy: interactions and reactions
656
Hepatitis C. Biomedical Research Reports: T. Jake Liang and Jay H. Hoofnagle (Eds.), Academic Press, 2000, ISBN 0-12-447870-0, $99.95
657
HEPATITIS C: A COMMON BUT INFREQUENTLY TREATED DISEASE
658
HEPATITIS C: A LEADING CAUSE OF CIRRHOSIS AT DHQ HOSPITAL D.I.KHAN
659
Hepatitis C: molecular virology and antiviral targets
660
Hepatitis C: prevalence and common genotypes among ethnic groups in Jeddah, Saudi Arabia
661
Hepatitis C: public health strategies
662
Hepatitis C: the clinical spectrum of the disease
663
Hepatitis C: the dermatologic profile
664
Hepatitis C-Associated Chronic Lymphoproliferative Disorders: A Single Center Experience
665
Hepatitis C-Associated Osteosclerosis After Blood Transfusion
666
Hepatitis C-Associated Osteosclerosis: An Unusual Syndrome of Acquired Osteosclerosis in Adults
667
Hepatitis C—virology and future antiviral targets
668
Hepatitis D and B virus genotypes in chronically infected patients from the Eastern Amazon Basin
669
Hepatitis D in Chronic Active Hepatitis B: Prevalence, Liver Enzyme levels and Histopathology-an Epidemiological Study in Shiraz, Southern Iran, 2003-2004
670
Hepatitis D Is a Forgotten Problem in Hemodialysis Patients in the World
671
Hepatitis D Virus Infection Among Hepatitis B Surface Antigen Carriers and in “Isolated anti-HBc” Antibodies Profile in Central Tunisia
672
Hepatitis D virus infection in Isfahan, central Iran: Prevalence and risk factors among chronic HBV infection cases
673
Hepatitis D virus infection in Kermanshah, west of Iran: seroprevalence and viremic infections
674
Hepatitis delta genotypes in chronic delta infection in the northeast of Spain (Catalonia)
675
Hepatitis disease diagnosis using a new hybrid system based on feature selection (FS) and artificial immune recognition system with fuzzy resource allocation
676
Hepatitis DVirus Infection among HIV-HBV Co-Infected Patients in Kermanshah, West of Iran
677
Hepatitis E antibodies and HIV status
678
Hepatitis E associated with surgical training on pigs
679
Hepatitis E in Brazil
680
HEPATITIS E SEROCONVERSION IN UNITED STATES TRAVELERS ABROAD
681
Hepatitis E Virus
682
Hepatitis E virus (HEV) infection in patients with cirrhosis is associated with rapid decompensation and death
683
Hepatitis E virus and HIV infection in homosexual men
684
Hepatitis E virus and pigs: A zoonotic risk in Europe?
685
Hepatitis E Virus and Renal Transplantation
686
Hepatitis E virus and serum level aminotransferases in blood donors
687
Hepatitis E Virus Circulation in Italy: Phylogenetic and Evolutionary Analysis
688
Hepatitis E virus genotyping based on full-length genome and partial genomic regions
689
Hepatitis E virus in Nepal: similarities with the Burmese and Indian variants
690
Hepatitis E virus infection
691
Hepatitis E Virus Infection Among Chronic Hemodialysis
692
Hepatitis E Virus Infection Among Iranian Patients with Beta-Thalassemia
693
Hepatitis E virus infection in a cohort of patients with acute non-A, non-B hepatitis
694
Hepatitis E Virus Infection in a Northern Mexican City: A Cross-Sectional Seroprevalence Study
695
Hepatitis E Virus Infection in Hemodialysis Patients: A Seroepidemiological Survey in Jahrom, Southern Iran
696
Hepatitis E Virus Infection in Iranian Kidney-Transplant Patients
697
Hepatitis E Virus Infection in Macaca Mulatta
698
Hepatitis E Virus Infection: A Neglected Problem in Our Region
699
Hepatitis E virus load in swine organs and tissues at slaughterhouse determined by real-time RT-PCR
700
Hepatitis E Virus Seroprevalence Among Blood Donors in Bushehr, South of Iran
701
Hepatitis E Virus Seroprevalence Among Liver Transplant Recipients with Persistent Elevation of Liver Enzymes: A Single Center Report
702
Hepatitis E Virus Seroprevalence and Viremia in Hemodialysis and HIV Infected Patients in Iran
703
Hepatitis E virus seroprevalence in haemodialysis patients in Zanjan province, Islamic Republic of Iran
704
Hepatitis E virus seroprevalence in HIV positive individuals in Shiraz, Southern Iran
705
Hepatitis E virus: complete genome sequence and phylogenetic analysis of a Nepali isolate
706
Hepatitis E: a virus in waiting
707
Hepatitis E: An emerging awareness of an old disease
708
Hepatitis E: Risk and Prevention
709
Hepatitis G viral RNA in Italian haemophiliacs with and without hepatitis C infection
710
Hepatitis G virus and fulminant hepatic failure: evidence for transfusion-related infection
711
Hepatitis G virus exposure in dialysis patients and blood donors in Isfahan‑Iran
712
Hepatitis G virus in immunosuppressed paediatric allograft recipients
713
Hepatitis G virus in India
714
Hepatitis G virus in Karachi, Pakistan
715
Hepatitis G virus in long-term survivors of haematological malignancy
716
Hepatitis G virus infection
717
Hepatitis G virus infection
718
Hepatitis G virus infection in chronic hepatitis C: frequency, features and response to interferon therapy
719
Hepatitis G Virus Infection in Iranian Blood Donors and High-Risk Groups
720
Hepatitis G-associated aplastic anaemia
721
Hepatitis GBV-C sequences in patients infected with HCV contaminated anti-D immunoglobulin and among i.v. drug users in Germany
722
Hepatitis in Ontario linked to EEG electrodes
723
Hepatitis induced by Kava (Piper methysticum rhizoma)
724
Hepatitis meeting suggests end of “carrier” status
725
Hepatitis Monthly, an International Journal in the Field of Hepatology
726
Hepatitis patients lost to follow-up at a liver centre in a tertiary care hospital of Karachi, Pakistan — a cross-sectional descriptive study
727
Hepatitis treatment in developing countries
728
Hepatitis treatment moves on
729
Hepatitis viral status affects the pattern of intrahepatic recurrence after resection for hepatocellular carcinoma
730
Hepatitis virus infection and atherosclerosis: reply to Vassalle, Zucchelli and Giustini
731
Hepatitis Virus Infection and Hodgkin s Lymphoma: A Review of the Literature
732
Hepatitis virus infections in heart transplant recipients
733
Hepatitis viruses and human immunodeficiency virus co-infection: pathogenisis and treatment
734
Hepatitis viruses and the MAPK pathway: is this a survival strategy?
735
Hepatitis Viruses B and D and Human Immunodeficiency Virus Infections in Hemodialysis Patients in the South of Iran: Prevalence and Genotypes
736
Hepatitis viruses in the XXI century
737
Hepatitis: A Rapidly Spreading Viral Infection in Pakistan
738
Hepatitis-B vaccine down under
739
Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation
740
Hepatitis-C and Hepatitis-B Co-Infections in Patients with Human Immunodeficiency Virus in Tehran, Iran
741
Hepatitis-C Infection Incidence Among the non-Hodgkin’s B-cell Lymphoma Patients in the Northeast of Iran
742
Hepatitis-C virus infection among injecting drug users in Lahore, Pakistan: A cross sectional study
743
Hepatitis-C virus infection among injecting drug users in Lahore, Pakistan: A cross sectional study
744
Hepatitis-C virus infection among injecting drug users in Lahore, Pakistan: A cross sectional study
745
Hepatitis-C-virus risk from Italian fertility centre
746
Hepatitis-E-associated fulminant hepatic failure in non-pregnant young women
747
Hepato- and Reno-Protective Impacts of Plantago major: An Experimental Model of Testicular Ischemia/Reperfusion
748
Hepato Protective and Antioxidant Role of Berberis tinctoria Lesch Leaves on Paracetamol Induced Hepatic Damage in Rats
749
Hepatoadrenal syndrome in Egyptian children with liver cirrhosis with and without sepsis
750
Hepatoatrial anastomosis and tricuspid valve replacement in budd-chiari syndrome 8.
751
Hepatobiliary and extra-hepatic malignancies in primary sclerosing cholangitis
752
Hepatobiliary carcinoma in primary sclerosing cholangitis: a case control study
753
Hepatobiliary Complications of Sickle Cell Disease among Children Admitted to Al Wahda Teaching Hospital, Aden, Yemen
754
Hepatobiliary Cystadenoma Mimicking Liver Hydatid Cyst
755
Hepatobiliary Cystadenoma with Mesenchymal Stroma Mistaken for Common Bile Duct Stone
756
Hepatobiliary excretion and brain distribution of caffeine in rats using microdialysis Original Research Article
757
Hepatobiliary excretion of 99mTc-EC: A potential source of mistake in the interpretation of renal scintigraphy
758
Hepatobiliary Excretion of Dipyrrinone Sulfonates in Mrp2-Deficient (TR−) Rats
759
Hepatobiliary Fascioliasis: Clinical and Radiological Features
760
Hepatobiliary Involvement in Neonates With COVID-19 Infection: A Narrative Review
761
Hepatobiliary organic anion transporters are differentially regulated in acute toxic liver injury induced by carbon tetrachloride
762
Hepatobiliary scintigraphy: An effective tool in the management of bile leak following laparoscopic cholecystectomy
763
Hepatobiliary surgeons meet immunologists: the case of colorectal liver metastases patients
764
Hepatobiliary surgery
765
HepatoBiliary Surgery and Nutrition - Message from the Editor-in-Chief
766
Hepatobiliary Surgery and Nutrition is indexed by SCIE: a tremendous step forward
767
Hepatobiliary surgery: the past, present, and future learned from Professor Henri Bismuth
768
Hepatobiliary transport
769
Hepatobiliary, renal and bone complications of intestinal failure
770
Hepatoblastoma in a 2-year-old child of a liver-transplanted mother
771
Hepatoblastoma in a patient with a partial trisomy 9p syndrome: a case report
772
Hepatoblastoma Related Tumor Thrombosis Extended to IVC, Ra and Pulmonary Artery Branches: A Case Report
773
Hepatoblastomas in Oman
774
Hepatocarcinogenesis inhibition by caffeine in ACI rats treated with 2-acetylaminofluorene
775
Hepatocarcinogenesis: A polygenic model of inherited predisposition to cancer
776
Hépatocarcinome traité par chémoembolisation et irradiation de haute dose: l’expérience lyonnaise
777
Hépatocarcinome traité par chémoembolisation et irradiation de haute dose: l’expérience lyonnaise
778
Hepatocellular adenoma displaying a HNF1α inactivation in a patient with familial adenomatous polyposis coli
779
Hepatocellular adenomas in patients taking danazol for here ditary angiooedema
780
Hepatocellular Cancer: A Guide for the Internist
781
Hepatocellular carcinoma
782
Hepatocellular carcinoma
783
Hepatocellular carcinoma
784
Hepatocellular carcinoma
785
Hepatocellular carcinoma
786
Hepatocellular carcinoma
787
Hepatocellular carcinoma
788
Hepatocellular carcinoma
789
Hepatocellular carcinoma (HCC) recurrence and what to do when it happens
790
Hepatocellular carcinoma after radiofrequency ablation therapy: Dynamic CT evaluation of treatment
791
Hepatocellular carcinoma after treatment with cyproterone acetate combined with ethinyloestradiol
792
Hepatocellular Carcinoma and Academic Skills Workshop cosponsored by Hepatobiliary Surgery and Nutrition and AME Publishing Company
793
Hepatocellular carcinoma and extrahepatic primary malignancy
794
Hepatocellular Carcinoma and Its Precursors in 103 HBV-Related Cirrhotic Explanted Livers: A Study from South Iran
795
Hepatocellular carcinoma and the art of prognostication
796
Hepatocellular carcinoma chemoprevention in chronic hepatitis B patients: all-in on statins?
797
Hepatocellular carcinoma development in cirrhosis
798
Hepatocellular Carcinoma Diagnosis Based on Ultrasound Images Using Feature Selection Techniques and K-nearest Neighbor Classifier
799
Hepatocellular carcinoma from diagnosis to treatment: 15 years of challenges and modification of resection strategies
800
Hepatocellular Carcinoma in a Boy with Progressive familial Intrahepatic Cholestasis Type II: Challenging Identification: Case report
801
Hepatocellular Carcinoma in a non-B non-C Non-alcoholic Steatohepatitis (NBNC-NASH HCC)
802
Hepatocellular carcinoma in a pregnant woman detected by routine screening of maternal α-fetoprotein
803
Hepatocellular carcinoma in a young survivor of major burns
804
Hepatocellular carcinoma in alcoholics
805
Hepatocellular Carcinoma in Dog – Case Report
806
HEPATOCELLULAR CARCINOMA IN EGYPTIANS WITH AND WITHOUT A HISTORY OF HEPATITIS B VIRUS INFECTION: ASSOCIATION WITH HEPATITIS C VIRUS (HCV) INFECTION BUT NOT WITH HCV RNA LEVEL
807
Hepatocellular Carcinoma in Explanted Livers of Patients with Genotype D HBV Cirrhosis: Report of the First Experience from Iran
808
Hepatocellular Carcinoma in Pakistan: Where do We Stand?
809
Hepatocellular carcinoma in patients suffering from primary sclerosing cholangitis
810
Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors
811
Hepatocellular carcinoma in patients with HCV
812
Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis
813
Hepatocellular Carcinoma in Port Harcourt, Nigeria: Clinicopathologic Study of 75 Cases
814
Hepatocellular Carcinoma in Pregnancy with Unusual Presentations
815
Hepatocellular Carcinoma in Sheep.
816
Hepatocellular Carcinoma in Sheep.
817
Hepatocellular carcinoma in situs inversus totalis-a case report
818
Hepatocellular Carcinoma in the World and the Middle East
819
Hepatocellular Carcinoma in Two Patients with Autoimmune Hepatitis, A Single Center Experience and Review of the Literature
820
Hepatocellular Carcinoma is an Emerging Issue Now in Iran
821
Hepatocellular carcinoma markers in the omics era: the glycomic analysis
822
Hepatocellular carcinoma on the increase in USA
823
Hepatocellular carcinoma with disseminated skeletal muscle metastasis
824
Hepatocellular carcinoma with extension into the right atrium
825
Hepatocellular Carcinoma With Intracavitary Cardiac Involvement: A Case Report and Review of the Literature
826
Hepatocellular carcinoma with macrovascular invasion treated with yttrium-90 radioembolization prior to transplantation
827
Hepatocellular carcinoma with progenitor cell features distinguishable by the hepatic stem/progenitor cell marker NCAM
828
Hepatocellular carcinoma with sarcomatous change arising after eradication of HCV via interferon therapy
829
Hepatocellular carcinoma without cirrhosis in the West: epidemiological factors and histopathology of the non-tumorous liver
830
Hepatocellular Carcinoma: A Pledge for Evidence-based Medicine
831
Hepatocellular carcinoma: an entity needed to be differentiated
832
Hepatocellular Carcinoma: An Uncommon Metastasis in the Orbit
833
Hepatocellular Carcinoma: An Update
834
Hepatocellular carcinoma: beyond screening
835
Hepatocellular carcinoma: conventional MRI findings including gadolinium-enhanced dynamic imaging. Review
836
Hepatocellular Carcinoma: First Manifestation as SolitaryHumeral Bone Metastasis
837
Hepatocellular Carcinoma: From Molecular Basis to Novel Treatment Approaches
838
Hepatocellular carcinoma: present status and future prospects
839
Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO
840
Hepatocellular Damage and Severity of COVID-19 Infection in Iraqi Patients: A Biochemical Study
841
Hepatocellular Expression of SIRT1 and Its Effect on Hepatocellular Carcinoma Progression: A Future Therapeutic Perspective
842
Hepatocellular functions of human liver cells in oxygen-permeable membrane device Original Research Article
843
Hepatocellular lesions with increased iron uptake on superparamagnetic iron oxide-enhanced magnetic resonance imaging in cirrhosis or chronic hepatitis: comparison of four magnetic resonance sequences for lesion conspicuity
844
Hepatocellular oxidative DNA injury induced by macrophage-derived nitric oxide
845
Hepatocellular oxidative stress and initial graft injury in human liver transplantation
846
Hepatocellular proliferation in patients with chronic hepatitis C and persistently normal or abnormal aminotransferase levels
847
Hepatocellular protection by nitric oxide or nitrite in ischemia and reperfusion injury
848
Hepatocellular recurrence after orthotopic liver transplantation: Is combination of α-fetoprotein and glypican-3 a reliable marker?
849
Hepatocellular sulfobromophthalein uptake at physiologic albumin concentrations: kinetic evidence for a high affinity/low capacity sinusoidal membrane system
850
HepatoConsult: a knowledge-based second opinion and documentation system
851
Hepatocurative activity of biosynthesized silver nanoparticles fabricated using Andrographis paniculata
852
Hepatocyte adhesion, growth and differentiated function on RGD-containing proteins
853
Hepatocyte and Islet Cell Cotransplantation on Poly-L-Lactide Matrix for the Treatment of Liver Cirrhosis
854
Hepatocyte apoptosis is a pathologic feature of human alcoholic hepatitis
855
Hepatocyte behavior on synthetic glycopolymer matrix: inhibitory effect of receptor–ligand binding on hepatocyte spreading
856
Hepatocyte culture on carbohydrate-modified star polyethylene oxide hydrogels
857
Hepatocyte growth factor (HGF) adsorption kinetics and enhancement of osteoblast differentiation on hydroxyapatite surfaces
858
Hepatocyte growth factor (HGF)-induced activation of the AP-1 complex : a comparison between normal and transformed rat hepatocytes
859
Hepatocyte growth factor activates endothelial proangiogenic mechanisms relevant in chronic hepatitis C-associated neoangiogenesis
860
Hepatocyte growth factor activates the AP-1 complex: a comparison between normal and transformed rat hepatocytes
861
Hepatocyte growth factor activates tumor stromal fibroblasts to promote tumorigenesis in gastric cancer
862
Hepatocyte growth factor and its actions in growth plate chondrocytes
863
Hepatocyte growth factor and placental development
864
Hepatocyte growth factor as a potential predictor of the presence of atherosclerotic aorto-iliac artery disease
865
Hepatocyte Growth Factor Attenuates the Severity of Status Epilepticus in Kainic Acid-induced Model of Temporal Lobe Epilepsy by Targeting Apoptosis and Astrogliosis
866
Hepatocyte growth factor in gingival crevicular fluid and the distribution of hepatocyte growth factor-activator in gingival tissue from adult periodontitis
867
Hepatocyte growth factor in human amniotic fluid promotes the migration of fetal small intestinal epithelial cells, ,
868
Hepatocyte growth factor induces activation of Nck and phospholipase C-γ in lung carcinoma cells
869
Hepatocyte growth factor induces collagenase (matrix metalloproteinase-1) via the transcription factor Ets-1 in human hepatic stellate cell line
870
Hepatocyte growth factor inhibits insulin-stimulated glycogen synthesis in primary cultured hepatocytes
871
Hepatocyte growth factor is a survival factor for endothelial cells and is expressed in human atherosclerotic plaques
872
Hepatocyte growth factor level in the vitreou of patient with proliferative vitreoretinopathy
873
Hepatocyte growth factor plays roles in the induction and autocrine maintenance of bone marrow stromal cell IL-11, SDF-1α, and stem cell factor
874
Hepatocyte growth factor prevents ventricular remodeling and dysfunction in mice via Akt pathway and angiogenesis
875
Hepatocyte growth factor protects cardiac myocytes against oxidative stress-induced apoptosis
876
Hepatocyte Growth Factor Regulation of Uterine Epithelial Cell Transepithelial Resistance and Tumor Necrosis Factor (alpha)Release in Culture
877
Hepatocyte growth factor/scatter factor in development, inflammation and carcinogenesis: its expression and role in oral tissues
878
Hepatocyte growth factor/scatter factor, angiogenesis and tumour cell proliferation in primary breast cancer
879
Hepatocyte growth factor: a multifunctional cytokine
880
Hepatocyte growth factor-induced proliferation of hepatic stem-like cells depends on activation of NF-κB
881
Hepatocyte IKKβ/NF-κB Inhibits Tumor Promotion and Progression by Preventing Oxidative Stress-Driven STAT3 Activation
882
Hepatocyte Isolation From Unused/Rejected Livers for Transplantation: Initial Step Toward Hepatocyte Transplantation, the First Experience From Iran
883
Hepatocyte Necrosis Induced by Oxidative Stress and IL-1α Release Mediate Carcinogen-Induced Compensatory Proliferation and Liver Tumorigenesis
884
Hepatocyte nuclear factor (HNF)-4α/γ, HNF-1α, and vHNF-1 regulate the cell-specific expression of the human dihydrodiol dehydrogenase (DD)4/AKR1C4 gene
885
Hepatocyte Nuclear Factor 1 α Controls Renal Expression of the Npt1-Npt4 Anionic Transporter Locus
886
Hepatocyte Nuclear Factor 4 Alpha Ligand Binding and F Domains Mediate Interaction and Transcriptional Synergy with the Pancreatic Islet LIM HD Transcription Factor Isl1
887
Hepatocyte Nuclear Factor 4 Is a Transcription Factor that Constitutively Binds Fatty Acids
888
Hepatocyte Nuclear Factor 4-Mediated Activation of Rat CYP3A1 Gene and Its Modes of Modulation by Apolipoprotein AI Regulatory Protein I and v-ErbA-Related Protein 3
889
Hepatocyte nuclear factor-4α plays pivotal roles in the regulation of mouse carboxylesterase 2 gene transcription in mouse liver
890
Hepatocyte performance on different crystallographic faces of rutile
891
Hepatocyte Polyploidy and Metabolism/Life-history Traits: Hypotheses Testing
892
Hepatocyte proliferation – can we target the mechanism?
893
Hepatocyte proliferation and serum hepatocyte growth factor levels in patients with alcoholic hepatitis
894
Hepatocyte proliferation in primary biliary cirrhosis as assessed by proliferating cell nuclear antigen and Ki-67 antigen labelling
895
Hepatocyte proliferative activity in human liver cirrhosis
896
Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3
897
Hepatocyte transplantation as a treatment for glycogen storage disease type 1a
898
Hepatocyte transplantation: emerging insights into mechanisms of liver repopulation and their relevance to potential therapies
899
Hepatocyte vacuolation and autolytic changes in the liver of pilot whales, Globicephala melas, stranded on Cape Cod, MA, USA
900
Hepatocyte-Derived MicroRNAS as Serum Predictors of Rejection of Liver Transplantation
901
Hepatocytes as a source of collagen type XVIII endostatin
902
Hepatocyte-stimulated expression of hepatocyte growth factor (HGF) in cultured rat hepatic stellate cells
903
Hepatocyte-supported serum-free culture of rat liver sinusoidal endothelial cells
904
Hepatoid carcinoma of the pancreas combined with serous cystadenoma: a case report and review of the literature
905
Hepatoid carcinoma of the pancreas mimicking neuroendocrine tumor
906
Hepatoid Variant of Yolk Sac Tumor of Both Ovaries With Widespread Intraabdominal and Lung Metastasis: A Case Report
907
Hepatologie : Edited by Gerok/Blum, 942, Urban & Schwarzenberg, US $ 398, ISBN 3-541-12272-2
908
Hepatology may have problems with putative surrogate outcome measures
909
Hepatoma-derived Growth Factor Represses SET and MYND Domain Containing 1 Gene Expression through Interaction with C-terminal Binding Protein
910
Hepatomegaly: A Major Clinical Sign in Some Metabolic Disorders
911
Hepatopancreas mitochondria of Mytilus galloprovincialis: effect of zinc ions on mitochondrial bioenergetics and metabolism
912
Hepatopancreatic nuclease of black tiger shrimp Penaeus monodon unlikely to be involved in viral triggered apoptosis
913
Hepatopathy and Reno-cardiopathy Induced by Ritalin in Rats
914
Hepatoprotection of sesquiterpenoids: A quantitative structure–activity relationship (QSAR) approach
915
Hepatoprotection of tea seed oil (Camellia oleifera Abel.) against CCl4-induced oxidative damage in rats
916
Hepatoprotective Activity of “Orthosiphon stamineus” on Liver Damage Caused by Paracetamol in Rats
917
Hepatoprotective activity of aerial parts of Otostegia persica against carbon tetrachloride-induced liver damage in rats
918
Hepatoprotective activity of Amaranthus spinosus in experimental animals
919
Hepatoprotective activity of Andrographis Paniculata and Swertia Chirayita
920
Hepatoprotective Activity of Camellia Sinensis and Its Possible Mechanism of Action
921
Hepatoprotective Activity of Capparis spinosa Root Bark Against CCl4 Induced Hepatic Damage in Mice
922
Hepatoprotective Activity of Caspian Saffron (Crocus caspius Fisch and Mey) Flowers against CCl4 Induced Acute Liver Injury in Mice
923
Hepatoprotective Activity of Cichorium intybus L. Leaves Extract Against Carbon Tetrachloride Induced Toxicity
924
Hepatoprotective activity of colocasia antiquorum against experimentally induced liver injury in rats
925
Hepatoprotective Activity of Cucumis trigonus Roxb. Fruit against CCl4 Inducesd Hepatic Damage in Rats
926
HEPATOPROTECTIVE ACTIVITY OF Iphiona grantioides AND Pluchea arguta FOR ACETAMINOPHEN INDUCED TOXICITY IN RABBITS
927
Hepatoprotective activity of Mammea africana ethanol stem bark extract
928
Hepatoprotective Activity of Momordica diocia Roxb Fruits in CCl4-Induced Hepatotoxicity in Rats
929
Hepatoprotective activity of phloretin and hydroxychalcones against Acetaminophen Induced hepatotoxicity in mice
930
HEPATOPROTECTIVE ACTIVITY OF PHYLLANTHUS RETICULATUS
931
Hepatoprotective activity of puerarin against carbon tetrachloride-induced injuries in rats: A randomized controlled trial
932
Hepatoprotective activity of royal jelly on mercuric chloride–induced damage model in rats
933
Hepatoprotective activity of Schouwia thebica webb
934
Hepatoprotective activity of the ethanol extract of Curcuma heyneana rhizome on isoniazid and rifampin-induced liver injury rats
935
Hepatoprotective Activity of the Ethanolic Extract of Ficus carica Linn. Leaves in Carbon Tetrachloride-Induced Hepatotoxicity in Rats
936
Hepatoprotective activity of the extract of Homalium letestui stem against paracetamol-induced liver injury
937
Hepatoprotective activity of the total flavonoids from Rosa laevigata Michx fruit in mice treated by paracetamol
938
Hepatoprotective amide constituents from the fruit of Piper chaba: Structural requirements, mode of action, and new amides Original Research Article
939
Hepatoprotective and antifibrotic effects of trans-chalcone against bile duct ligation-induced liver fibrosis in rats
940
Hepatoprotective and antiobesity effects of mirabegron, a novel β3-adrenoceptor agonist, on carbon tetrachloride-induced hepatotoxicity in obese rats
941
Hepatoprotective and Antioxidant Activities of Combination of Cinnamomum zeylanicum and Zingiber officinale in CCl4intoxicated Rats
942
Hepatoprotective and antioxidant activity of ethanolic extracts of edible lotus (Nelumbo nucifera Gaertn.) leaves
943
Hepatoprotective and Antioxidant Activity of Euphorbia tirucalli
944
Hepatoprotective and antioxidant effects of Azolla microphylla based gold nanoparticles against acetaminophen induced toxicity in a fresh water common carp fish (Cyprinus carpio L.)
945
Hepatoprotective and antioxidant effects of Bupleurum kaoi Liu (Chao et Chuang) extract and its fractions fractionated using supercritical CO2 on CCl4-induced liver damage
946
Hepatoprotective and antioxidant effects of Commiphora berryi (Arn) Engl bark extract against CCl4-induced oxidative damage in rats
947
Hepatoprotective and Antioxidant Effects of Eupatorium ayapana against Carbon Tetrachloride Induced Hepatotoxicity in Rats
948
Hepatoprotective and antioxidant effects of lycopene in acute cholestasis
949
Hepatoprotective and Anti-oxidant effects of Nepeta Ispahanica Boiss extract on CCL4 induced liver Injury
950
Hepatoprotective and antioxidant effects of porcine plasma protein hydrolysates on carbon tetrachloride-induced liver damage in rats
951
Hepatoprotective and antioxidant effects of the coffee diterpenes kahweol and cafestol on carbon tetrachloride-induced liver damage in mice
952
Hepatoprotective and antioxidant polyphenols from a standardized methanolic extract of the leaves of Liquidambar styraciflua L.
953
Hepatoprotective and antioxidative effects of total phenolics from Laggera pterodonta on chemical-induced injury in primary cultured neonatal rat hepatocytes
954
Hepatoprotective and Hypolipidemic Effects of Carthamus tinctorius oil in Alloxan-induced Type 1 Diabetic Rats
955
Hepatoprotective and Hypolipidemic Effects of Satureja Khuzestanica Essential Oil in Alloxan-induced Type 1 Diabetic Rats
956
Hepatoprotective and hypolipidemic effects of water-soluble polysaccharidic extract of Pleurotus eryngii
957
Hepatoprotective and nitric oxide production inhibitory activities of coumarin and polyacetylene constituents from the roots of Angelica furcijuga
958
Hepatoprotective constituents from Zedoariae Rhizoma: absolute stereostructures of three new carabrane-type sesquiterpenes, curcumenolactones A, B, and C Original Research Article
959
Hepatoprotective effect and antioxidant role of sun, sulphited-dried apricot (Prunus armeniaca L.) and its kernel against ethanol-induced oxidative stress in rats
960
Hepatoprotective effect and mechanistic insights of deoxyelephantopin, a phyto-sesquiterpene lactone, against fulminant hepatitis
961
Hepatoprotective Effect of 17β-Estradiol as Antioxidant Modulators Against Stress Damage
962
Hepatoprotective effect of 2,3-dehydrosilybin on carbon tetrachloride-induced liver injury in rats
963
Hepatoprotective effect of Acantholimon bracteatum (Girard) Boiss. on formaldehyde-induced liver injury in adult male mice
964
Hepatoprotective Effect of Adenema hyssopifolium G. Don (Gentianaceae) in Carbon Tetrachloride-Induced Hepatotoxicity in Rats
965
Hepatoprotective Effect of Allium hooshidaryae Hydroalcoholic Extract on Acetaminophen-Induced Hepatotoxicity in Male Rats
966
Hepatoprotective Effect of Alpha Lipoic Acid Against Bromobenzene-Induced Liver Damage in Rats
967
Hepatoprotective Effect of an Indian Salt Marsh Herb Suaeda Monoica Forsk. Ex. Gmel Against Concanavalin-A Induced Toxicity in Rats
968
Hepatoprotective Effect of Aqueous Extract of Persian Gulf Brown Algae Sargassum swartzii Against Acetaminophen-Induced Hepatotoxicity in Mice
969
HEPATOPROTECTIVE EFFECT OF CARNOSINE ON LIVER BIOCHEMICAL PARAMETERS IN CHRONIC ETHANOL INTOXICATED RAT
970
Hepatoprotective effect of chitooligosaccharides against tert-butylhydroperoxide-induced damage in Chang liver cells
971
Hepatoprotective Effect of Coenzyme Q10 in Rats with Diclofenac Toxicity
972
Hepatoprotective Effect of Cornus mas Fruits Extract Against Carbon Tetrachloride-Induced Hepatic Damage in Male Albino Rats
973
Hepatoprotective effect of Crocus sativus (saffron) petals extract against acetaminophen toxicity in male Wistar rats
974
Hepatoprotective effect of Descurainia sophia seed extract against paracetamol-induced oxidative stress and hepatic damage in mice
975
Hepatoprotective effect of Descurainia sophia seed extract against paracetamol-induced oxidative stress and hepatic damage in mice
976
Hepatoprotective effect of electrolyzed reduced water against carbon tetrachloride-induced liver damage in mice
977
Hepatoprotective Effect of Ethanolic Extract of Lavandula officinalis L. in Alloxan-Induced Diabetic Rats
978
hepatoprotective effect of ethanolic extract of lavandula officinalis l.in alloxan-induced diabetic rats
979
Hepatoprotective Effect of Ficus carica Leaf Extract on Mice Intoxicated with Carbon Tetrachloride
980
HEPATOPROTECTIVE EFFECT OF GARLIC (ALLIUM SATIVUM) AND MILK THISTLE (SILYMARIN) IN ISONIAZID INDUCED HEPATOTOXICITY IN RATS
981
Hepatoprotective Effect of Glycyrrhiza Glabra in Carbon Tetrachloride-Induced Model of Acute Liver Injury
982
Hepatoprotective effect of herbal drug on CCl4 induced liver damage
983
Hepatoprotective effect of kaempferol glycosides isolated from Cedrela odorata L. leaves in albino mice: involvement of Raf/MAPK pathway
984
Hepatoprotective Effect of Lactobacillus Plantarum Against Salmonella Typhimurium in Mice
985
Hepatoprotective Effect of Matricaria chamomilla Hot Aqueous Extract Against Methomyl 90%- Induced Hepatotoxicity In Mice
986
Hepatoprotective Effect of Microemulsion-Based System of
Prunus Cerasus
Kernel Extract on CCL
4
-induced Liver Damage in Mice
987
HEPATOPROTECTIVE EFFECT OF MORUS ALBA L. IN CARBON TETRACHLORIDE- INDUCED HEPATOTOXICITY IN MICE
988
HEPATOPROTECTIVE EFFECT OF MORUS ALBA L. IN CARBON TETRACHLORIDE- INDUCED HEPATOTOXICITY IN MICE
989
Hepatoprotective effect of mulberry water extracts on ethanol-induced liver injury via anti-inflammation and inhibition of lipogenesis in C57BL/6J mice
990
Hepatoprotective Effect of Otostegia persica Boiss. Shoot Extract on Carbon Tetrachloride-Induced Acute Liver Damage in Rats
991
Hepatoprotective effect of polyphenols rich methanolic extract of Amorphophallus commutatus var. wayanadensis against CCl4 induced hepatic injury in swiss albino mice
992
Hepatoprotective Effect of Pomegranate (Punica Granatum) Fruit Juice and Seed Extracts against CCL4-Induced Toxicity
993
Hepatoprotective effect of Rosa canina fruit extract against carbon tetrachloride induced hepatotoxicity in rat
994
Hepatoprotective effect of Rosmarinus officinalis and rosmarinic acid on acetaminophen-induced liver damage
995
Hepatoprotective Effect of Satureja Khuzestanica Essential Oil and Vitamin E in Experimental Hyperthyroid Rats: Evidence for Role of Antioxidant Effect
996
Hepatoprotective Effect of Satureja Khuzestanica Essential Oil and Vitamin E in Experimental Hyperthyroid Rats: Evidence for Role of Antioxidant Effect
997
Hepatoprotective effect of silyamarin in individuals chronically exposed to hydrogen sulfide; modulating influence of TNF-α cytokine genetic polymorphism
998
Hepatoprotective Effect of Silymarin and Propolis in Chemically Induced Chronic Liver Injury in Rats
999
Hepatoprotective effect of the root extract of Decalepis hamiltonii against carbon tetrachloride-induced oxidative stress in rats
1000
Hepatoprotective effect of the root extract of green tea against malathion-induced oxidative stress in rats
